These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 10487608)
1. Preclinical evaluation of the cardiac toxicity of HMR-1826, a novel prodrug of doxorubicin. Platel D; Bonoron-Adèle S; Dix RK; Robert J Br J Cancer; 1999 Sep; 81(1):24-7. PubMed ID: 10487608 [TBL] [Abstract][Full Text] [Related]
2. Preclinical assessment of anthracycline cardiotoxicity in laboratory animals: predictiveness and pitfalls. Robert J Cell Biol Toxicol; 2007 Jan; 23(1):27-37. PubMed ID: 17041747 [TBL] [Abstract][Full Text] [Related]
3. Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention. Pouna P; Bonoron-Adèle S; Gouverneur G; Tariosse L; Besse P; Robert J Br J Pharmacol; 1996 Apr; 117(7):1593-9. PubMed ID: 8730759 [TBL] [Abstract][Full Text] [Related]
4. Comparison of three approaches to doxorubicin therapy: free doxorubicin, liposomal doxorubicin, and beta-glucuronidase-activated prodrug (HMR 1826). Woessner R; An Z; Li X; Hoffman RM; Dix R; Bitonti A Anticancer Res; 2000; 20(4):2289-96. PubMed ID: 10953287 [TBL] [Abstract][Full Text] [Related]
5. Morphine is protective against doxorubicin-induced cardiotoxicity in rat. Kelishomi RB; Ejtemaeemehr S; Tavangar SM; Rahimian R; Mobarakeh JI; Dehpour AR Toxicology; 2008 Jan; 243(1-2):96-104. PubMed ID: 17988779 [TBL] [Abstract][Full Text] [Related]
6. Enhanced uptake of doxorubicin into bronchial carcinoma: beta-glucuronidase mediates release of doxorubicin from a glucuronide prodrug (HMR 1826) at the tumor site. Mürdter TE; Sperker B; Kivistö KT; McClellan M; Fritz P; Friedel G; Linder A; Bosslet K; Toomes H; Dierkesmann R; Kroemer HK Cancer Res; 1997 Jun; 57(12):2440-5. PubMed ID: 9192823 [TBL] [Abstract][Full Text] [Related]
7. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors. Robert J Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818 [TBL] [Abstract][Full Text] [Related]
8. Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment. Nazeyrollas P; Frances C; Prevost A; Costa B; Lorenzato M; Kantelip JP; Elaerts J; Millart H Anticancer Res; 2003; 23(1A):405-9. PubMed ID: 12680240 [TBL] [Abstract][Full Text] [Related]
9. The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat. Rahimi Balaei M; Momeny M; Babaeikelishomi R; Ejtemaei Mehr S; Tavangar SM; Dehpour AR Eur J Pharmacol; 2010 Sep; 641(2-3):193-8. PubMed ID: 20534381 [TBL] [Abstract][Full Text] [Related]
10. Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats. Giri SN; Al-Bayati MA; Du X; Schelegle E; Mohr FC; Margolin SB Cancer Chemother Pharmacol; 2004 Feb; 53(2):141-50. PubMed ID: 14564477 [TBL] [Abstract][Full Text] [Related]
11. Acute exercise protects against doxorubicin cardiotoxicity. Wonders KY; Hydock DS; Schneider CM; Hayward R Integr Cancer Ther; 2008 Sep; 7(3):147-54. PubMed ID: 18815146 [TBL] [Abstract][Full Text] [Related]
12. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress. Li W; Xu B; Xu J; Wu XL Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):192-7. PubMed ID: 19143757 [TBL] [Abstract][Full Text] [Related]
13. [The prevention of the myocardial toxicity of doxorubicin with superoxide dismutase]. Villani F; Galimberti M; Favalli L; Rozza A; Lanza E; Poggi P G Ital Cardiol; 1991 Jun; 21(6):633-41. PubMed ID: 1743445 [TBL] [Abstract][Full Text] [Related]
14. Dosing time dependency of doxorubicin-induced cardiotoxicity and bone marrow toxicity in rats. To H; Ohdo S; Shin M; Uchimaru H; Yukawa E; Higuchi S; Fujimura A; Kobayashi E J Pharm Pharmacol; 2003 Jun; 55(6):803-10. PubMed ID: 12841941 [TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity of doxorubicin/paclitaxel combination in rats: effect of sequence and timing of administration. Saad SY; Najjar TA; Alashari M J Biochem Mol Toxicol; 2004; 18(2):78-86. PubMed ID: 15122649 [TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of the cardiac toxicity of 4'-deoxy-doxorubicin. Villani F; Galimberti M; Comazzi R; Crippa F; Bonfante V; Ferrari L; Pacciarini MA Int J Clin Pharmacol Ther Toxicol; 1988 Apr; 26(4):185-9. PubMed ID: 3403095 [TBL] [Abstract][Full Text] [Related]
18. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart. Plandé J; Platel D; Tariosse L; Robert J Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573 [TBL] [Abstract][Full Text] [Related]
19. Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase. Mürdter TE; Friedel G; Backman JT; McClellan M; Schick M; Gerken M; Bosslet K; Fritz P; Toomes H; Kroemer HK; Sperker B J Pharmacol Exp Ther; 2002 Apr; 301(1):223-8. PubMed ID: 11907177 [TBL] [Abstract][Full Text] [Related]
20. [Pharmacokinetics of cyclophosphamide, adriamycin and adriamycin prodrug (HMR 1928) using an ex vivo isolated perfused human lung model (IHLP)]. Mürdter TE; Linder A; Friedel G; McClellan M; Bohnenstengel F; Sperker B; Kroemer HK; Toomes H; Freitag L; Fritz P Pneumologie; 2000 Nov; 54(11):494-8. PubMed ID: 11132546 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]